UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 1-U
CURRENT REPORT PURSUANT TO REGULATION A
Date of Report (Date of earliest event reported): April 1, 2022
BALANCED PHARMA INCORPORATED
(Exact name of issuer as specified in its charter)
| Delaware | 85-2855195 | |
| (State or other jurisdiction of | (IRS Employer | |
| incorporation or organization) | Identification No.) |
| 18204 Mainsail Pointe Cornelius, NC | 28031 | |
| (Address of principal executive offices) | (Zip code) |
(704) 650-0249
(Issuer’s telephone number, including area code)
Common Stock
(Title of each class of securities issued pursuant to Regulation A)
Item 9. Other Events
On April 1, 2022, Balanced Pharma Incorporated (the “Company”) and Dalmore Group, LLC., (“Dalmore”) entered into a Broker-Dealer Agreement (the “Amendment”). This Amendment replaces in its entirety Exhibit 1.1 that was dated January 10, 2022, and previously filed with the Securities Exchange Commission (the “Commission”) on March 23, 2022.
On July 14, 2022, the Company and Dalmore entered into an addendum (the “Addendum”) to the Amendment in which the Company agreed to pay Dalmore a fee of 6% for any funds the Company raises through the platform operated by Justly Markets, LLC. The Addendum is filed as Exhibit 1.2 to this Current Report on Form 1-U.
Filing of Underwriting Agreements
SIGNATURE
Pursuant to the requirements of Regulation A, the issuer has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in City of Cornelius, State of North Carolina, on July 19, 2022.
| BALANCED PHARMA INCORPORATED | |
| /s/ J. Scott Keadle | |
| By: J. Scott Keadle, Chief Executive Officer |
